Global Neuropathic Pain Market to Reach US$10.7 Billion by 2030
The global market for Neuropathic Pain estimated at US$8.3 Billion in the year 2024, is expected to reach US$10.7 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Anticonvulsant segment is estimated at 2.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.1% CAGR
The Neuropathic Pain market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.
Global Neuropathic Pain Market - Key Trends & Drivers Summarized
Why Is Neuropathic Pain Recognition and Treatment Gaining Critical Momentum in Chronic Pain Management?
Neuropathic pain, a complex and often debilitating form of chronic pain caused by nerve damage or dysfunction, has emerged as a significant clinical concern with far-reaching implications for quality of life, mental health, and healthcare utilization. Unlike nociceptive pain, which results from tissue injury or inflammation, neuropathic pain arises from lesions in the peripheral or central nervous system and is often characterized by burning, tingling, electric shock-like sensations, or hypersensitivity. Common causes include diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced neuropathy, multiple sclerosis, spinal cord injuries, and trigeminal neuralgia.
The rising prevalence of diabetes, cancer survivorship, and neurological disorders is contributing to a global surge in neuropathic pain diagnoses. However, due to its subjective nature and resistance to conventional analgesics, neuropathic pain is frequently underdiagnosed and undertreated. Clinical guidelines increasingly emphasize early identification and multidimensional therapy involving pharmacological, interventional, and psychological modalities. As awareness grows among both clinicians and patients, the demand for effective and well-tolerated pharmacotherapies is accelerating, propelling the growth of the neuropathic pain treatment market.
How Are Pharmacological Advances and Personalized Treatment Strategies Improving Outcomes in Neuropathic Pain?
Current pharmacological treatments for neuropathic pain include first-line agents such as gabapentinoids (gabapentin, pregabalin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), topical lidocaine or capsaicin, and opioids as a last resort. These therapies aim to modulate neural signaling, inhibit neurotransmitter release, or desensitize pain receptors. However, variable efficacy, tolerability issues, and the risk of dependence have spurred interest in alternative and adjunctive therapies.
Recent innovations include sodium channel blockers (e.g., lacosamide), calcium channel modulators, cannabinoid-based therapies, and gene therapy targeting pain-specific receptors. Non-invasive neuromodulation techniques-such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS)-are being incorporated into multimodal pain management protocols. Advances in pain phenotyping, quantitative sensory testing, and digital pain tracking are enabling more tailored and dynamic treatment strategies. These developments are redefining how chronic neuropathic pain is approached-shifting from trial-and-error prescribing to evidence-informed, patient-specific care pathways.
Which Patient Cohorts and Regional Healthcare Systems Are Driving the Neuropathic Pain Market?
Key patient groups driving the neuropathic pain market include individuals with diabetes (especially those with painful diabetic peripheral neuropathy), cancer survivors undergoing chemotherapy, elderly patients with post-stroke or post-surgical nerve damage, and individuals with spinal disorders or multiple sclerosis. Gender disparities are also observed, with women reporting higher pain intensity and treatment resistance. Chronic pain prevalence is notably higher in aging populations, further intensifying demand in regions with demographic imbalances.
North America leads the market due to high healthcare spending, widespread chronic disease burden, and robust access to pain management specialists. Europe follows with strong clinical guidelines and a growing focus on non-opioid pain control solutions. Asia-Pacific is experiencing significant growth due to rapid urbanization, rising diabetes prevalence, and expanding access to specialty care in countries like India, China, and Japan. Latin America and parts of Africa remain underdiagnosed markets but are expected to grow through telemedicine, mobile health apps, and public awareness campaigns targeting chronic pain literacy.
What Is Powering Long-Term Innovation and Commercial Expansion in the Neuropathic Pain Market?
The growth in the neuropathic pain market is fueled by increasing disease incidence, improved diagnostic capabilities, and innovation in targeted therapies that address underlying neurological dysfunction. As opioid stewardship becomes a global priority, investment is flowing into alternative analgesics with better safety and efficacy profiles. R&D pipelines are expanding to include biologics, ion channel modulators, RNA-based therapeutics, and monoclonal antibodies that target neural inflammation and pain sensitization pathways.
Regulatory bodies are supporting novel product approvals through expedited pathways, especially for therapies addressing unmet needs in rare or treatment-refractory pain syndromes. Companion diagnostics and digital health integrations are enabling dynamic dose titration and better adherence monitoring. As chronic pain management becomes a multidisciplinary endeavor, the neuropathic pain market is poised for sustained growth-anchored by a shift toward precision medicine, integrated care, and patient-centric outcomes that extend beyond mere symptom suppression.
SCOPE OF STUDY:
The report analyzes the Neuropathic Pain market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Other Drug Classes); Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications); Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 44 Featured) -
AbbVie Inc.
Akelos Inc.
Averitas Pharma, Inc.
BioLineRx Ltd.
Bristol-Myers Squibb Company
Dogwood Therapeutics
Eli Lilly and Company
GlaxoSmithKline plc (GSK)
Grunenthal GmbH
Johnson & Johnson
Lexicon Pharmaceuticals, Inc.
Mallinckrodt Pharmaceuticals
Neuropathix Inc.
Pfizer Inc.
Sanofi S.A.
SiteOne Therapeutics
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Trevena, Inc.
Vertex Pharmaceuticals Incorporated
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Neuropathic Pain - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Diabetes and Chemotherapy-Induced Neuropathy Propels Demand for Neuropathic Pain Therapies
Emergence of Novel Ion Channel Modulators Expands Treatment Portfolio and Market Penetration
Regulatory Approvals of Dual-Mechanism Analgesics Strengthen Business Case for Neuropathic Pain Drugs
Advancements in Peripheral Nerve Stimulation Techniques Drive Adoption of Device-Based Therapies
Increased Recognition of Central Sensitization Pathways Spurs Innovation in Drug Targets
Availability of Extended-Release Formulations Enhances Patient Adherence and Therapy Outcomes
Clinical Emphasis on Early Diagnosis Supports Preventive Pharmacological Interventions
Rising Demand for Non-Addictive Analgesics Spurs Interest in Novel Drug Mechanisms
Availability of Neuropathic Pain Biomarkers Strengthens Role of Predictive Diagnostics
Challenges in Regulatory Approval Timelines Pose Delays for First-in-Class Therapies
Growing Use of CBD-Derived Formulations Expands Alternative Pain Management Landscape
Integration of Artificial Intelligence in Drug Repurposing Enhances Pipeline Diversification
Increased Patient Awareness Through Advocacy Campaigns Generates Therapy Demand
Regional Variability in Pain Management Guidelines Creates Fragmentation in Market Penetration
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Neuropathic Pain Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Anticonvulsant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Capsaicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Drugs Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Diabetic Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Spinal Stenosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
CANADA
TABLE 50: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Canada 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
JAPAN
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 59: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Japan 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
CHINA
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 68: China Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: China 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
EUROPE
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 77: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
FRANCE
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 89: France Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: France Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: France 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
GERMANY
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 98: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Germany 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
ITALY
TABLE 107: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Italy 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
UNITED KINGDOM
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 116: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: UK Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: UK 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
SPAIN
TABLE 125: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 131: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Spain 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
RUSSIA
TABLE 134: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 140: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Russia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Rest of Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
AUSTRALIA
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 164: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Australia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 170: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Australia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
INDIA
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 173: India Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: India 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 179: India Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: India Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: India 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 182: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: South Korea 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 188: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: South Korea 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
LATIN AMERICA
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 200: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 212: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Argentina 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 218: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Argentina 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
BRAZIL
TABLE 221: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Brazil 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 227: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Brazil 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
MEXICO
TABLE 230: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Mexico 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 236: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Mexico 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
MIDDLE EAST
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 248: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
IRAN
TABLE 260: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Iran 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 266: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Iran 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
ISRAEL
TABLE 269: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Israel 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 275: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Israel 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 287: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: UAE 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 293: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: UAE 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
AFRICA
Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 305: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Africa 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 311: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 313: Africa 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030